Advertisement
Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment
(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday that it has completed bioanalytical method development under its prior agreement with Altasciences.
The company now plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
The blood and plasma samples collected are part of a dose response study in a humanized mouse model.
The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
read more
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews
|
595 days ago
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.
RTTNews
|
851 days ago
Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
RTTNews
|
951 days ago
Domino's Pizza Q1 Earnings Beat, Revenues Miss, U.S. Same Store Sales Down; Stock Drops
Domino's Pizza Inc. announced Monday higher earnings in its first quarter, above market estimates, amid revenue growth. Meanwhile, the largest pizza company in the world recorded weak income from operations and U.S. same store sales, and its top line missed the Street view. In pre-market activity on the Nasdaq, Domino's Pizza shares were losing around 2.6 percent.
RTTNews
|
2h 7min ago
Bay Street Likely To Open On Mixed Note
The Canadian market is likely to open on a mixed note on Monday with investors mostly making cautious moves, as the nation goes to the polls today.
RTTNews
|
2h 14min ago
Pound Rises As European Shares Traded Higher
The British pound strengthened against other major currencies in the European session on Monday amid increased risk appetite, as tariff tensions eased and investors looked ahead to a busy week of earnings, with four of the Magnificent Seven companies— Amazon, Apple, Meta Platforms and Microsoft — due to report their quarterly results.
RTTNews
|
2h 53min ago
Pound Rises Against Majors
The British pound strengthened against other major currencies in the European session on Monday.
RTTNews
|
3h 20min ago
FTSE Up Marginally In Cautious Trade
The U.K. market is marginally up at noon on Monday with investors making some selective purchases ahead of a slew of corporate earnings announcements and some crucial economic data this week.
Optimism about U.S. and China striking a trade deal sometime soon is also contributing to the positive mood in the market.
RTTNews
|
3h 45min ago
